Clinical Trail Of Gatifloxacin Eye Drop In Treatment Of Acute Bacterial Conjunctivitis

BACKGROUNDAcute bacterial conjunctivitis, which is common and frequently encountered disease in out-patient, is characterized by high infective bacteria and happens in summer and autumn often. It is not hard to diagnose and treat it but it is hard in clinical drug treatment for the sake of more and more resistant bacteria come from the abuse of antibiotics. The third fluroquino is one kind of antibiotics which is often used in ophthalmology. It's antibacterial activity for Gram-negative bacteria is better than that for Gram-positive bacteria and it is the weakest for anaerobe and endo-pathogens. Gatifloxacin is the fourth generation fluroquino antibiotics, it not only has the antibiotic activity for Gram-negative bacteria, but also strengthen the antibiotic for bacteria including Gram-positive bacteria such as MRSA, anaerobe, mycoplsma, and mycobacteria. It is characterized by the wide antibacterial spectrum, powerful antibiotic activity, wide tissue distribution, long elimination half-life, few side effects, low photosensitivity, etc. Gatifloxin has been confirmed that it is effective for respiratory infection, genitourinary infection, skin and soft tissue inflection. 0.3% Gatifloxacin eye drop is manufactured by Kyorin pharma co .Ltd and is at the third period of clinical trial. Gatifloxacin eye drop is agreed to Allergan Pharma co Ltd, and has been agreed to go on the market by FDA of America on 31st, March, 2003. The trade name is Zymar。 Gatifloxacin eye solution made in China had not been used generally. Gatifloxacin eye drop made in China was the...